Journal of Inborn Errors of Metabolism and Screening (May 2015)

β-Galactosidase Deficiency in Colombia

  • Alfredo Uribe PhD,
  • Adis Ayala MSc,
  • Monica España MSc,
  • Isidro Arevalo MSc,
  • Natalia Pacheco MSc,
  • Lina M. Jay Garcia MSc

DOI
https://doi.org/10.1177/2326409815586252
Journal volume & issue
Vol. 3

Abstract

Read online

β-Galactosidase (BGal) is the first enzyme involved in the catabolism of sphingolipids. Two pathologies have been directly associated with its deficiency: GM1 gangliosidosis and Morquio B. Morquio B is among the rarest types of mucopolysaccharidosis (MPS). We aim to document the β-galactosidase deficiency in Colombia. We evaluated leukocytes from 1492 healthy Colombian individuals and 923 patients, referred between 2005 and August 2014. Dried blood spot (DBS) samples from the same number of patients were evaluated. β-Galactosidase was measured with 4-methylumbelliferyl-β- d -galactoside. As a control enzyme, the total hexosaminidase activity was also evaluated. We identified 14 patients with GM1 gangliosidosis, 5 patients with Morquio B, and 1 patient with I-cell disease. We could establish a reference value for Bgal in Colombian leukocyte samples. GM1 gangliosidosis is the main pathology associated with a direct deficiency of BGal. The high number of patients found with MPS IVB indicates that there are patients who could be misdiagnosed due to an unawareness of the disease.